샘플 요청 목록

 카트 문의
시장보고서
상품코드
1659424

차세대 암 진단약 시장

Next Generation Cancer Diagnostics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 89 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 차세대 암 진단약 시장, 2030년에는 미국에서 646억 달러에 달할 전망

2024년에 198억 달러로 추정되는 세계의 차세대 암 진단약 시장은 분석 기간인 2024-2030년에 21.8%의 CAGR로 성장하며, 2030년에는 646억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 qPCR & Multiplexing Technology는 CAGR 22.8%를 기록하며, 분석 기간 종료시에는 282억 달러에 달할 것으로 예측됩니다. 차세대 시퀀스 기술 분야의 성장률은 분석 기간 중 CAGR 17.9%로 추정됩니다.

미국 시장은 57억 달러로 추정, 중국은 CAGR 21.0%로 성장 예측

미국의 차세대 암 진단약 시장은 2024년에 57억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 99억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 21.0%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 19.3%와 18.0%로 예측됩니다. 유럽에서는 독일이 CAGR 약 14.8%로 성장할 것으로 예측됩니다.

세계의 차세대 암 진단약 시장 - 주요 동향과 촉진요인 정리

차세대 암 진단약은 어떻게 종양학에 혁명을 일으키고 있는가?

차세대 암 진단법(NGCD)은 다양한 암의 조기 발견, 정확한 진단, 맞춤 치료를 위한 첨단 툴을 제공하며 종양학 분야의 비약적인 발전을 상징합니다. 이러한 진단법은 액체생검, 유전체학, 유전체학, 단백질학, 차세대 염기서열 분석(NGS) 등 다양한 기술을 포괄하고 있습니다. 기존 진단과 달리 NGCD는 상세한 분자적 인사이트을 제공하므로 암 전문의가 암 진행을 촉진하는 유전자 돌연변이 및 바이오마커를 이해할 수 있습니다. 이러한 정확성은 표적 치료를 가능하게 하여 환자의 예후를 개선하고 부작용을 줄일 수 있습니다. 전 세계에서 암 유병률이 증가하는 가운데, NGCD는 보다 개인화되고, 신속하고, 효과적인 암 치료를 실현함으로써 암 치료의 변화에 중요한 역할을 하고 있습니다.

차세대 암 진단 시장의 주요 부문은?

주요 기술로는 액체생검, NGS, 단백질체학, 생물정보학, 생물정보학 툴 등이 있으며, 액체생검과 NGS는 비침습적 특성과 유전자 변화를 감지하는 능력으로 인해 큰 지지를 받고 있습니다. 응용 측면에서 NGCD는 스크리닝, 진단 검사, 치료 반응 모니터링에 사용되고 있습니다. 유방암, 폐암, 대장암과 같은 조기 암 검진은 조기 발견을 통해 생존율을 크게 향상시킬 수 있는 주요 용도이며, NGCD의 주요 최종사용자로는 병원, 진단 실험실, 연구 기관이 있으며, 이들 모두는 암 관리의 정확성과 효율성을 높이기 위해 이러한 기술을 임상 워크플로우에 통합하고 있습니다. 워크플로우에 통합하고 있습니다.

NGCD 기술은 헬스케어 분야 간 어떻게 통합되고 있는가?

병원과 종양센터는 특히 고위험군 환자 및 유전성 암 증후군 환자를 대상으로 NGCD를 일상적인 암 검진 및 진단 프로토콜에 통합하고 있습니다. 진단 실험실는 NGCD를 사용하여 유전체 및 단백질체 검사를 수행하여 특정 돌연변이 및 치료 옵션을 식별하고 정밀의료를 지원합니다. 연구기관은 임상시험 수행, 암 유전체학 연구, 신약 타깃 발굴을 위해 이러한 진단법을 활용하고 있습니다. 제약사들도 NGCD 개발자와 협력하여 약물의 효능을 예측하는 바이오마커를 찾아내어 약품 개발을 개선하고 임상시험을 가속화하고 있습니다. 또한 원격의료 플랫폼은 원격 환자 모니터링을 위해 NGCD를 통합하기 시작했으며, 암 진단을 더욱 친숙하게 만들고 있습니다.

차세대 암 진단약 시장 성장을 가속하는 요인은?

차세대 암 진단 시장의 성장은 암 유병률 증가로 인해 보다 효과적인 스크리닝 및 진단 툴에 대한 수요가 증가하는 등 여러 가지 요인에 의해 주도되고 있습니다. 유전체학 및 단백질체학의 발전으로 인한 맞춤형 의료로의 전환은 NGCDs의 채택을 더욱 촉진하고 있습니다. 액체생검 기술의 급속한 발전은 NGS 플랫폼의 개선과 함께 진단 정확도를 높여 NGCD를 현대 종양학에 필수적인 요소로 만들었습니다. 또한 암 연구 및 진단 기술 혁신에 대한 규제 당국의 승인과 정부의 자금 지원도 시장 성장에 기여하고 있습니다. 또한 암 조기 발견에 대한 인식이 높아지고 유전자 검사 서비스가 확대됨에 따라 헬스케어 부문 전반에서 NGCD에 대한 수요가 증가하고 있습니다.

부문

기술(qPCR & multiplexing, 차세대 시퀀싱, LOAC &RT-PCR, 기타 기술), 기능(치료 모니터링, 동반진단, 예후 진단, 암스크리닝, 리스크 분석), 용도(바이오마커 개발, CTC 분석, 프로테옴 분석, 유전자 분석, 기타 용도)

조사 대상 기업의 예(주목 33사)

  • Abbott
  • Agilent Technologies
  • Almac Group
  • Cepheid
  • F. Hoffmann-La Roche Ltd
  • GE Healthcare
  • Genomic Health
  • Hologic
  • Illumina
  • Janssen Global Services
  • Koninklijke Philips N.V
  • Myriad Genetics
  • Novartis AG
  • Opko Health
  • PerkinElmer
  • Qiagen
  • Sysmex Corporation
  • Thermo Fisher Scientific

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장의 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

KSA 25.03.07

Global Next Generation Cancer Diagnostics Market to Reach US$64.6 Billion by 2030

The global market for Next Generation Cancer Diagnostics estimated at US$19.8 Billion in the year 2024, is expected to reach US$64.6 Billion by 2030, growing at a CAGR of 21.8% over the analysis period 2024-2030. qPCR & Multiplexing Technology, one of the segments analyzed in the report, is expected to record a 22.8% CAGR and reach US$28.2 Billion by the end of the analysis period. Growth in the Next Generation Sequencing Technology segment is estimated at 17.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.7 Billion While China is Forecast to Grow at 21.0% CAGR

The Next Generation Cancer Diagnostics market in the U.S. is estimated at US$5.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$9.9 Billion by the year 2030 trailing a CAGR of 21.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 19.3% and 18.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.8% CAGR.

Global Next Generation Cancer Diagnostics Market - Key Trends and Drivers Summarized

How Are Next Generation Cancer Diagnostics Revolutionizing Oncology?

Next Generation Cancer Diagnostics (NGCD) represent a leap forward in the field of oncology, offering advanced tools for early detection, accurate diagnosis, and personalized treatment of various cancers. These diagnostics encompass a broad range of technologies, including liquid biopsy, genomics, proteomics, and next-generation sequencing (NGS). Unlike traditional diagnostics, NGCDs provide detailed molecular insights, enabling oncologists to understand the genetic mutations and biomarkers that drive cancer progression. This precision enables targeted therapies, improving patient outcomes and reducing side effects. As the prevalence of cancer rises globally, NGCDs are playing a critical role in transforming cancer care by making it more personalized, faster, and more effective.

What Are The Key Segments in the Next Generation Cancer Diagnostics Market?

Key technologies include liquid biopsy, NGS, proteomics, and bioinformatics tools, with liquid biopsy and NGS gaining significant traction due to their non-invasive nature and ability to detect genetic alterations. In terms of applications, NGCDs are used in screening, diagnostic testing, and monitoring treatment response. Screening for early-stage cancers, such as breast, lung, and colorectal cancers, is a major application segment, where early detection significantly improves survival rates. Major end-users of NGCDs include hospitals, diagnostic laboratories, and research institutes, all of which are integrating these technologies into clinical workflows to enhance precision and efficiency in cancer management.

How Are NGCD Technologies Being Integrated Across Healthcare Sectors?

Hospitals and oncology centers are integrating NGCDs into routine cancer screening and diagnostic protocols, particularly for high-risk patients and those with hereditary cancer syndromes. Diagnostic laboratories use NGCDs to perform genomic and proteomic tests that aid in identifying specific mutations and treatment options, supporting precision medicine. Research institutes are leveraging these diagnostics to conduct clinical trials, study cancer genomics, and explore new drug targets. Pharmaceutical companies also collaborate with NGCD developers to identify biomarkers that predict drug efficacy, thereby improving drug development and accelerating clinical trials. Additionally, telehealth platforms are beginning to incorporate NGCDs for remote patient monitoring, making cancer diagnostics more accessible.

What Factors Are Driving the Growth in the Next Generation Cancer Diagnostics Market?

The growth in the Next Generation Cancer Diagnostics market is driven by several factors, including the increasing prevalence of cancer, which has heightened the demand for more effective screening and diagnostic tools. The shift toward personalized medicine, driven by advancements in genomics and proteomics, has further fueled the adoption of NGCDs. The rapid development of liquid biopsy technologies, coupled with improvements in NGS platforms, has enhanced diagnostic accuracy, making NGCDs indispensable in modern oncology. Regulatory approvals and government funding for cancer research and diagnostic innovation are also contributing to market growth. Additionally, the growing awareness of early cancer detection and the expansion of genetic testing services have increased the demand for NGCDs across healthcare sectors.

SCOPE OF STUDY:

The report analyzes the Next Generation Cancer Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR, Other Technologies); Function (Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, Risk Analysis); Application (Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 33 Featured) -

  • Abbott
  • Agilent Technologies
  • Almac Group
  • Cepheid
  • F. Hoffmann-La Roche Ltd
  • GE Healthcare
  • Genomic Health
  • Hologic
  • Illumina
  • Janssen Global Services
  • Koninklijke Philips N.V
  • Myriad Genetics
  • Novartis AG
  • Opko Health
  • PerkinElmer
  • Qiagen
  • Sysmex Corporation
  • Thermo Fisher Scientific

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Next Generation Cancer Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Early and Accurate Cancer Detection Spurs Growth in Next Generation Cancer Diagnostics Market
    • Technological Advancements in Liquid Biopsy and Genomic Testing Strengthen Business Case for Adoption
    • Growing Focus on Personalized and Precision Medicine Expands Addressable Market
    • Expansion of Next Generation Diagnostics in Oncology Clinics and Hospitals Fuels Market Growth
    • Increasing Adoption of Next Generation Diagnostics in Biomarker Discovery and Targeted Therapy Expands Market Opportunities
    • Technological Innovations in Multi-Omics Analysis and AI-Powered Diagnostics Propel Market Expansion
    • Rising Focus on Non-Invasive Testing and Monitoring Drives Demand for Next Generation Cancer Diagnostics
    • Growing Use of Next Generation Diagnostics in Screening Programs and Clinical Trials Expands Market Potential
    • Technological Advancements in ctDNA, CTC, and Circulating miRNA Testing Propel Market Growth
    • Increasing Focus on Integrating Next Generation Cancer Diagnostics with Digital Health Platforms Drives Adoption
    • Rising Demand for Companion Diagnostics in Immuno-Oncology and Targeted Therapies Strengthens Global Market
    • Expansion of Next Generation Cancer Diagnostics in Rare and Pediatric Cancers Expands Market Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World 6-Year Perspective for Next Generation Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for qPCR & Multiplexing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 4: World 6-Year Perspective for qPCR & Multiplexing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World 6-Year Perspective for Next Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for LOAC & RT-PCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World 6-Year Perspective for LOAC & RT-PCR by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 10: World 6-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Biomarker Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World 6-Year Perspective for Biomarker Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for CTC Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World 6-Year Perspective for CTC Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 15: World Recent Past, Current & Future Analysis for Proteomic Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 16: World 6-Year Perspective for Proteomic Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Genetic Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World 6-Year Perspective for Genetic Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 21: World Recent Past, Current & Future Analysis for Therapeutic Monitoring by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 22: World 6-Year Perspective for Therapeutic Monitoring by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Companion Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World 6-Year Perspective for Companion Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Prognostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 26: World 6-Year Perspective for Prognostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 27: World Recent Past, Current & Future Analysis for Cancer Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 28: World 6-Year Perspective for Cancer Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Risk Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World 6-Year Perspective for Risk Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 31: World Next Generation Cancer Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: USA 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 36: USA Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: USA 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Canada 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • JAPAN
    • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Japan 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Japan 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • CHINA
    • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 52: China Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: China 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 54: China Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: China 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • EUROPE
    • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for Next Generation Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 58: Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Europe 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 60: Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Europe 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • FRANCE
    • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 64: France Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: France 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 66: France Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: France 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • GERMANY
    • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 70: Germany Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Germany 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 72: Germany Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Germany 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • ITALY
    • TABLE 76: Italy Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Italy 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 78: Italy Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Italy 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • UNITED KINGDOM
    • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 82: UK Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: UK 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 84: UK Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: UK 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 88: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of Europe 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 90: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of Europe 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 94: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Asia-Pacific 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 96: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Asia-Pacific 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 100: Rest of World Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Rest of World 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 102: Rest of World Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Rest of World 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 104: Rest of World Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of World 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제